PUNE, India, August 30, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Autism - Pipeline Review, H2 2016" market research report that provides an overview of the Autism's therapeutic pipeline with comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.
Complete report on H2 2016 pipeline review of Autism with 42 market data tables and 16 figures, spread across 134 pages is available at http://www.rnrmarketresearch.com/autism-pipeline-review-h2-2016-market-report.html .
Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history. The report also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Autism Pipeline Review, H2 2016 report include Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc., AgeneBio Inc., APeT Holding BV, BioCrea GmbH, BrainStorm Cell Therapeutics Inc., Cellceutix Corporation, Confluence Pharmaceuticals LLC, Coronis Partners Ltd., Curemark, LLC, F. Hoffmann-La Roche Ltd., GW Pharmaceuticals Plc, Heptares Therapeutics Limited, Intra-Cellular Therapies, Inc., MedDay SA, Omeros Corporation, Otsuka Holdings Co., Ltd., Retrophin Inc., Saniona AB and Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles mentioned in this research are (dextromethorphan + quinidine sulfate), acamprosate calcium, ACT-01, ADX-71441, ADX-88178, aripiprazole, carbetocin, CB-0306, CM-AT, Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome, GWP-42006, histamine dihydrochloride, HTL-14242, ITI-007, KM-391, lurasidone hydrochloride, MD-1103, niacinamide CR, NurOwn, oxytocin, RG-7314, SF-999, Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism, Small Molecule to Agonize GABRA5 Receptor for CNS Disorders, Small Molecule to Block Chloride Channels for Autism, Small Molecule to Target GPR63 for Autism, Small Molecule to Target Oxytocin for Autism and Anxiety Disorders, Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism, Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome, Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology, Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure and Synthetic Peptide for Autism and Alzheimer's Disease.
Order a copy of H2 2016 autism pipeline market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=674886 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Autism and reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Autism therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Autism.
Another newly published market research report titled on Diabetic Neuropathic Pain - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are APT Therapeutics, Inc., Astellas Pharma Inc., BioDelivery Sciences International, Inc., Bristol-Myers Squibb Company, Centrexion Therapeutics Corp, Chromocell Corporation, Daiichi Sankyo Company, Limited, Grunenthal GmbH, Hydra Biosciences, Inc., Immune Pharmaceuticals Inc., Laboratorios Del Dr. Esteve S.A., Lohocla Research Corporation, Novaremed, PeriphaGen, Inc., Pharmaleads SA, Prismic Pharmaceuticals, Inc., Relmada Therapeutics, Inc., Sphaera Pharma Pvt. Ltd. and Theravasc, Inc. Diabetic Neuropathic Pain Pipeline market research report of 95 pages is available at http://www.rnrmarketresearch.com/diabetic-neuropathic-pain-pipeline-review-h2-2016-market-report.html .
Explore more reports on Neurology therapeutics.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
SOURCE RnR Market Research